List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4277582/publications.pdf Version: 2024-02-01



RIÃON ROÃ1/CHED

#	Article	IF	CITATIONS
1	In memoriam Professor Dr. Philipp A. Schnabel (1953–2021). 40pen, 2022, 5, 7.	0.1	Ο
2	Initiative on #4openScienceStandsForUkraine scientists and students. 4open, 2022, 5, E2.	0.1	1
3	War against Ukraine: Humanitarian aid and how much morality can science bear. 40pen, 2022, 5, E3.	0.1	Ο
4	COVID-19: Pandemic surgery guidance. 4open, 2020, 3, 1.	0.1	48
5	Chronic inflammation evoked by pathogenic stimulus during carcinogenesis. 4open, 2019, 2, 8.	0.1	10
6	Eicosanoids in carcinogenesis. 4open, 2019, 2, 9.	0.1	8
7	NF-lºB signaling and crosstalk during carcinogenesis. 40pen, 2019, 2, 13.	0.1	16
8	Microbiome and morbid obesity increase pathogenic stimulus diversity. 40pen, 2019, 2, 10.	0.1	5
9	Prelude and premise to the special issue: disruption of homeostasis-induced signaling and crosstalk in the carcinogenesis paradigm "Epistemology of the origin of cancerâ€. 40pen, 2019, 2, 6.	0.1	0
10	Undervalued ubiquitous proteins. 40pen, 2019, 2, 7.	0.1	6
11	Transition from normal to cancerous cell by precancerous niche (PCN) induced chronic cell-matrix stress. 40pen, 2019, 2, 14.	0.1	5
12	Metformin alters signaling induced crosstalk and homeostasis in the carcinogenesis paradigm "Epistemology of the origin of cancer― 40pen, 2019, 2, 12.	0.1	0
13	Precancerous niche (PCN), a product of fibrosis with remodeling by incessant chronic inflammation. 4open, 2019, 2, 11.	0.1	5
14	Synopsis: Special Issue on "Disruption of signaling homeostasis induced crosstalk in the carcinogenesis paradigm Epistemology of the origin of cancer― 40pen, 2019, 2, 28.	0.1	1
15	Science belongs to no one—and to everyone. 40pen, 2018, 1, E1.	0.1	8
16	Somatic Mutation Theory - Why it's Wrong for Most Cancers. Cellular Physiology and Biochemistry, 2016, 38, 1663-1680.	1.1	65
17	Future Directions for the Early Detection of Colorectal Cancer Recurrence. Journal of Cancer, 2014, 5, 272-280.	1.2	45
18	Current Approaches and Challenges for Monitoring Treatment Response in Colon and Rectal Cancer. Journal of Cancer, 2014, 5, 31-43.	1.2	64

#	Article	IF	CITATIONS
19	Early Detection of Colorectal Cancer Recurrence in Patients Undergoing Surgery with Curative Intent: Current Status and Challenges. Journal of Cancer, 2014, 5, 262-271.	1.2	110
20	Cell-Cell Communication in the Tumor Microenvironment, Carcinogenesis, and Anticancer Treatment. Cellular Physiology and Biochemistry, 2014, 34, 213-243.	1.1	170
21	Treatment of acute abdominal pain in the emergency room: A systematic review of the literature. European Journal of Pain, 2014, 18, 902-913.	1.4	50
22	Future Directions for Monitoring Treatment Response in Colorectal Cancer. Journal of Cancer, 2014, 5, 44-57.	1.2	40
23	Current Approaches, Challenges and Future Directions for Monitoring Treatment Response in Prostate Cancer. Journal of Cancer, 2014, 5, 3-24.	1.2	78
24	Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 1-3.	0.7	12
25	Anorectal Malignant Melanoma: Extensive 45-Year Review and Proposal for a Novel Staging Classification. Journal of the American College of Surgeons, 2013, 217, 324-335.	0.2	59
26	Colorectal cancer stem cells as biomarkers: Where it all starts?. Journal of Surgical Oncology, 2013, 107, 791-793.	0.8	2
27	Preoperative assessment of peritoneal carcinomatosis: intraindividual comparison of 18F-FDG PET/CT and MRI. Abdominal Imaging, 2013, 38, 64-71.	2.0	75
28	The Diagnostic and Prognostic Role of microRNA in Colorectal Cancer - a Comprehensive review. Journal of Cancer, 2013, 4, 281-295.	1.2	70
29	Multi-Parametric MRI-Directed Focal Salvage Permanent Interstitial Brachytherapy for Locally Recurrent Adenocarcinoma of the Prostate: A Novel Approach. Journal of Cancer, 2013, 4, 146-151.	1.2	14
30	Patients at Risk for Peritoneal Surface Malignancy of Colorectal Cancer Origin: The Role of Second Look Laparotomy. Journal of Cancer, 2013, 4, 262-269.	1.2	10
31	Evidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions. Journal of Cancer, 2013, 4, 172-192.	1.2	14
32	Tumor-Infiltrating Immune Cells Promoting Tumor Invasion and Metastasis: Existing Theories. Journal of Cancer, 2013, 4, 84-95.	1.2	146
33	Significance of Infectious Agents in Colorectal Cancer Development. Journal of Cancer, 2013, 4, 227-240.	1.2	62
34	Serum-Based DNA Methylation Biomarkers in Colorectal Cancer: Potential for Screening and Early Detection. Journal of Cancer, 2013, 4, 210-216.	1.2	38
35	Tumor response criteria: are they appropriate?. Future Oncology, 2012, 8, 903-906.	1.1	5
36	Randomized Clinical Trials for Colorectal Cancer Peritoneal Surface Malignancy. Surgical Oncology Clinics of North America, 2012, 21, 665-688.	0.6	15

#	Article	IF	CITATIONS
37	Peritoneal Carcinomatosis: Cytoreductive Surgery and HIPEC–-Overview and Basics. Cancer Investigation, 2012, 30, 209-224.	0.6	84
38	Peritoneal carcinomatosis: comparison of dynamic contrast-enhanced magnetic resonance imaging with surgical and histopathologic findings. Abdominal Radiology, 2012, 37, 834-842.	1.0	31
39	Experience after 100 patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World Journal of Gastroenterology, 2012, 18, 2061.	1.4	10
40	Barrett's esophagus: treatments of adenocarcinomas I. Annals of the New York Academy of Sciences, 2011, 1232, 248-264.	1.8	4
41	Barrett's esophagus: treatments of adenocarcinomas II. Annals of the New York Academy of Sciences, 2011, 1232, 265-291.	1.8	1
42	Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned. Langenbeck's Archives of Surgery, 2011, 396, 1077-1081.	0.8	23
43	Tumor suppressor gene adenomatous polyposis coli downregulates intestinal transport. Pflugers Archiv European Journal of Physiology, 2011, 461, 527-536.	1.3	6
44	Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin. International Journal of Oncology, 2011, 39, 1593-600.	1.4	13
45	Application of Laser Microdissection and Quantitative PCR to Assess the Response of Esophageal Cancer to Neoadjuvant Chemo-Radiotherapy. Methods in Molecular Biology, 2011, 755, 197-202.	0.4	1
46	The predictive value of genes of the TGF-β1 pathway in multimodally treated squamous cell carcinoma of the esophagus. International Journal of Colorectal Disease, 2010, 25, 515-521.	1.0	11
47	Effort, safety, and findings of routine preoperative endoscopic evaluation of morbidly obese patients undergoing bariatric surgery. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 1996-2001.	1.3	102
48	Non-acid Gastroesophageal Reflux Measured Using Multichannel Intraluminal Impedance in Older Patients. Journal of Gastrointestinal Surgery, 2010, 14, S17-S23.	0.9	1
49	Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer. International Journal of Cancer, 2010, 126, 1513-1520.	2.3	121
50	Phosphoglycerate Kinase 1 Promoting Tumor Progression and Metastasis in Gastric Cancer - Detected in a Tumor Mouse Model Using Positron Emission Tomography/Magnetic Resonance Imaging. Cellular Physiology and Biochemistry, 2010, 26, 147-154.	1.1	40
51	Transient Lower Esophageal Sphincter Relaxation and Esophageal Motor Response. Journal of Surgical Research, 2010, 159, 714-719.	0.8	24
52	Local Peritonectomy Highly Attracts Free Floating Intraperitoneal Colorectal Tumour Cells in a Rat Model. Cellular Physiology and Biochemistry, 2009, 23, 371-378.	1.1	10
53	Surgery of Colorectal Carcinoma in Patients Aged over 80. Oncology Research and Treatment, 2009, 32, 10-16.	0.8	6
54	Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy. International Journal of Colorectal Disease, 2009, 24, 69-77.	1.0	16

#	Article	IF	CITATIONS
55	Multichannel Intraluminal Impedance Measurement of Gastroesophageal Reflux in Patients with Different Stages of Morbid Obesity. Obesity Surgery, 2009, 19, 1522-1529.	1.1	29
56	Morbid Obesity and Subsequent Pancreatic Cancer: Pylorus-Preserving Pancreatoduodenectomy after Laparoscopic Sleeve Gastrectomy. Obesity Surgery, 2009, 19, 385-388.	1.1	6
57	Transient Lower Esophageal Sphincter Relaxation in Morbid Obesity. Obesity Surgery, 2009, 19, 595-600.	1.1	61
58	IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunology, Immunotherapy, 2009, 58, 153-157.	2.0	281
59	Response to Preoperative Therapy in Upper Gastrointestinal Cancers. Annals of Surgical Oncology, 2009, 16, 878-886.	0.7	33
60	18F-FDG-PET/CT to Select Patients with Peritoneal Carcinomatosis for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2009, 16, 1295-1303.	0.7	141
61	Synchronous adenocarcinoma of the lung and neuroendocrine carcinoma of the ileum. International Journal of Colorectal Disease, 2008, 23, 325-327.	1.0	7
62	Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. British Journal of Cancer, 2008, 99, 1020-1026.	2.9	31
63	Potential Combination Chemotherapy Approaches for Advanced Adult-Type Soft-Tissue Sarcoma. American Journal of Clinical Dermatology, 2008, 9, 207-217.	3.3	20
64	PGK1 a Potential Marker for Peritoneal Dissemination in Gastric Cancer. Cellular Physiology and Biochemistry, 2008, 21, 429-436.	1.1	63
65	Distinct Functionality of Tumor Cell–Derived Gelatinases during Formation of Liver Metastases. Molecular Cancer Research, 2008, 6, 341-351.	1.5	22
66	Glomus Tumor of the Stomach Simulating a Gastrointestinal Stromal Tumor: A Case Report and Review of Literature. Case Reports in Gastroenterology, 2008, 2, 1-5.	0.3	18
67	Amelanotic Esophageal Malignant Melanoma: Case Report and Short Review of the Literature. Case Reports in Gastroenterology, 2008, 2, 224-231.	0.3	14
68	Tissue Inhibitor of Metalloproteinases-1 Promotes Liver Metastasis by Induction of Hepatocyte Growth Factor Signaling. Cancer Research, 2007, 67, 8615-8623.	0.4	133
69	The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. British Journal of Cancer, 2007, 97, 1404-1408.	2.9	42
70	Squamous cell carcinoma and Zenker diverticulum. Ecological Management and Restoration, 2007, 20, 75-78.	0.2	27
71	VEGF-C Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus. World Journal of Surgery, 2007, 31, 1768-1772.	0.8	35
72	Esophageal squamous cell carcinoma with entirely intramural growth pattern. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 862-866	1.4	16

Björn Brù∕4cher

#	Article	IF	CITATIONS
73	Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor β1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine. British Journal of Surgery, 2006, 93, 1424-1432.	0.1	22
74	The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer, 2006, 106, 2119-2127.	2.0	131
75	Hypermethylation ofhMLH1,HPP1,p14ARF,p16INK4A andAPC in primary adenocarcinomas of the small bowel. International Journal of Cancer, 2006, 119, 1298-1302.	2.3	32
76	No association of primary adenocarcinomas of the small bowel with Epstein-Barr virus infection. Molecular Carcinogenesis, 2006, 45, 349-352.	1.3	10
77	Early Esophageal Cancer. Annals of Surgery, 2005, 242, 566-575.	2.1	399
78	Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment. Journal of Clinical Oncology, 2004, 22, 900-908.	0.8	448
79	Histologic Tumor Type Is an Independent Prognostic Parameter in Esophageal Cancer: Lessons From More Than 1,000 Consecutive Resections at a Single Center in the Western World. Annals of Surgery, 2001, 234, 360-369.	2.1	452
80	Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma: Response Evaluation by Positron Emission Tomography. Annals of Surgery, 2001, 233, 300-309.	2.1	340
81	Achalasia and Esophageal Cancer: Incidence, Prevalence, and Prognosis. World Journal of Surgery, 2001, 25, 745-749.	0.8	149
82	Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma. Cancer, 2001, 92, 2228-2233.	2.0	78
83	Esophageal cancer: patient evaluation and pre-treatment staging. Surgical Oncology, 2001, 10, 103-111.	0.8	63
84	Ischemic spinal cord syndrome after transthoracic esophagectomy: two cases of a rare neurologic complication. Ecological Management and Restoration, 2000, 13, 328-332.	0.2	6
85	Prognostic Factors in Resected Primary Small Bowel Tumors. Digestive Surgery, 1998, 15, 42-51.	0.6	44
86	Intramural esophageal hematoma after cardioversion. Ecological Management and Restoration, 1997, 10, 225-228.	0.2	8